Taipei – October 15, 2026 -- MetaTech AP Inc. (TPEx: 3224) reported revenue of NT$1.391 billion for the first nine months of 2026, up 21% year over year. The company outlined its 2027 strategy at an investor conference, with electronics and biomedicine as its two growth engines.
Electronics revenue rises 24.7% on AI server and power supply demand
The electronics business grew 24.7% year over year in the first nine months. MetaTech AP is pursuing opportunities in AI servers, power supplies and semiconductors. For 2027, it plans to strengthen AI-related applications and sales in the segment.
Zheng Yang Biomedical to sell MetaTech AP-made human platelet lysate worldwide
MetaTech AP has expanded its collaboration with Zheng Yang Biomedical. MetaTech AP will manufacture human platelet lysate (hPL), and Zheng Yang Biomedical will lead global sales and marketing. The partnership targets demand for cell culture materials that reduce reliance on animal-derived inputs, improve culture quality and safety, and prepare for potentially stricter regulation.
The companies are also developing Elate Ocular®, a regenerative medicine product for dry eye disease. Plans include clinical trials and regulatory approval in Taiwan, with local manufacturing by MetaTech AP. GlobalData projected the dry eye therapeutics market would grow at a 10.6% CAGR from 2018 to 2028, reaching US$11.1 billion (about NT$356.9 billion).
MetaTech AP and Locus Cell target intelligent CDMO status in Taiwan
Chairman Alex Chen said MetaTech AP and its consolidated subsidiary Locus Cell are moving toward an i CDMO (intelligent Contract Development and Manufacturing Organization) model. He said the aim is to "establish Taiwan as a local production base for regenerative medicine" and to become a preferred global manufacturing partner for cell therapy products.
AI-powered GMP document generation and review systems have cut average processing time for relevant documentation tasks by about one-third, according to the company. It says this lowers labor and operational costs.
iPSC licensing link with iPS Academia Japan anchors Japanese talks
MetaTech Group holds a commercial licensing relationship on iPSC technology with Japan's iPS Academia Japan, associated with CiRA. It continues discussions with Japanese partners on iPSC-derived cell therapy products. The company has worked in regenerative medicine since 2013, covering cell therapy and iPSC programs.
In 2027, MetaTech AP will advance clinical trials, regulatory submissions and local manufacturing in biomedicine. With Locus Cell, it will also pursue additional international i CDMO opportunities.